|
|
Phase II Randomized Study of Zileuton for the Prevention of Lung Cancer in Patients With Bronchial Dysplasia
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase II | Prevention | Closed | 18 and over | WSU-D-2405 WSU-093201MP4F, NCT00056004 |
Objectives - Determine the efficacy of zileuton, in terms of number of sites and grade of dysplastic lesions in the bronchial epithelium, in patients with documented bronchial dysplasia.
- Correlate the regression of bronchial dysplasia (number and grade) and improvement in sputum cytology with the modulation of molecular biomarkers in patients treated with this drug.
- Determine the overall toxicity of this drug in these patients.
- Determine the 6-month natural history of bronchial dysplasia in patients who are randomized to receive treatment with a placebo.
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy Endocrine therapy - More than 3 months since prior corticosteroids*
- No concurrent corticosteroids*
- No concurrent anticancer hormonal agents
[Note: *Systemic or inhaled, including chronic administration] Radiotherapy - No concurrent radiotherapy
Surgery Other - More than 3 months since prior lipoxygenase inhibitors*
- More than 3 months since prior investigational agents
- More than 3 months since prior nutritional supplements (except 1 daily multivitamin)
- No concurrent nutritional supplements (except 1 daily multivitamin)
- No other concurrent lipoxygenase inhibitors*
- No other concurrent investigational agents
- No concurrent warfarin, beta-blockers, or theophylline
- No other concurrent antineoplastic agents
- No concurrent or chronic daily use of non-steroidal anti-inflammatory agents (NSAIDS) (except cardioprotective doses of aspirin less than 100 mg/day)
- Periodic use of NSAIDS allowed
- Concurrent participation in a smoking cessation program (including use of bupropion or nicotine gum or patch) allowed
[Note: *Systemic or inhaled, including chronic administration] Patient Characteristics:
Age - 18 and over (for patients with prior lung or head and neck malignancy)
- 35 and over (for all other patients)
Performance status Life expectancy Hematopoietic - WBC at least 3,000/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 10.0 g/dL
- No bleeding disorder
Hepatic - Bilirubin no greater than upper limit of normal (ULN)
- Liver enzymes no greater than ULN
- PT/PTT no greater than ULN
- No active or chronic liver disease (even if transaminases have normalized)
Renal - Creatinine no greater than ULN
Cardiovascular - No unstable angina
- No uncontrolled heart failure
Pulmonary - No significant asthma or chronic obstructive pulmonary disease requiring chronic or periodic (at least once per year) steroids for flares
- No acute or chronic respiratory failure
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing and able to undergo serial bronchoscopic examinations
- No ongoing alcohol use (i.e., at least 1 glass of wine, beer, or a mixed drink per day on a regular basis)
- No other medical condition that would preclude safety during study participation
- No other active or invasive malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
- No hypersensitivity to study drug or any of its inactive ingredients
Expected Enrollment 134Approximately 134 patients will be accrued for this study. Outcomes Primary Outcome(s)Bronchial dysplasia number and grade at 6 months
Secondary Outcome(s)Biomarkers (Ki-67, Cyclin D1, bcl-2, bax, caspase-3) by immunohistochemistry at 6 and 12 months Biomarkers (5-HETE, LTB-4) by blood and BAL levels at 6 and 12 months
Adverse events as measured by number and severity monthly
Outline This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to smoking status (current vs recently quit smoker), and prior cancer (none vs lung or head and neck). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral zileuton 4 times daily for 6 months in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo 4 times daily for 6 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks.
Trial Contact Information
Trial Lead Organizations Barbara Ann Karmanos Cancer Institute | | | Omer Kucuk, MD, Protocol chair | | | |
Related Information Featured trial article
Registry Information | | Official Title | | Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia | | Trial Start Date | | 2002-09-27 | | Registered in ClinicalTrials.gov | | NCT00056004 | | Date Submitted to PDQ | | 2003-01-28 | | Information Last Verified | | 2006-12-12 | | NCI Grant/Contract Number | | N01-CN05022 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|